Log in |
Faik G. Uzunoglu MD, Caroline Kaufmann, Harriet Wikman PhD, Cenap Güngör DSc, Benjamin A. Bohn MD, Michael F. Nentwich MD, Matthias Reeh MD, Klaus Pantel, Maximilian Bockhorn PhD, Asad Kutup MD, Oliver Mann PhD, Jakob R. Izbicki, Yogesh K. Vashist MD
View full article HTML | View full article PDF | Download Citation
VEGFR-2 gene displays several functional germline polymorphisms with impact on VEGFR-2 mediated angiogenesis. Our purpose was to evaluate VEGFR-2 polymorphisms as prognostic markers for tumor recurrence and overall survival (OS) in non-small-cell lung cancer (NSCLC).
In total, 209 Caucasian patients who had been surgically treated for NSCLC between 1996 and 2010 were included in this study. Genotyping of peripheral blood cells was performed by TaqMan® genotyping assays or polymerase chain reaction for five VEGFR-2 polymorphisms. Chi- square test, Kaplan–Meier estimator, and Cox regression hazard model were used to assess the prognostic value of VEGFR-2 polymorphisms.
VEGFR-2+4422 (AC)10–14 polymorphism was identified as a positive prognostic marker for time to metastasis (11/12 vs. 11/11 (AC) repeats: hazard ratio (HR), 0.28; 95% confidence interval (CI), 0.11–0.75; p = 0.012) and OS (11/12 vs. 11/11 (AC) repeats: HR, 0.41; 95% CI, 0.21–0.82; p = 0.012) in squamous cell carcinoma. For adenocarcinoma, VEGFR-2−906 C>T (C/T vs. CC: HR, 0.19; 95% CI, 0.43–0.82; p = 0.027) and VEGFR-2−271 G>A (G/A vs. G/G: HR, 0.25; 95% CI, 0.07–0.86; p = 0.027) predicted longer time to local recurrence and VEGFR-2−906 C>T was a predictor for better OS (T/T vs. C/C: HR, 0.28; 95% CI, 0.09–0.84; p = 0.024).
VEGFR2 germline polymorphisms predict tumor recurrence and OS in NSCLC.
Go to Issue Contents
Add this article to your Personal Archive
Effective January 2013, there will be a processing fee of $50 USD for each initial new submission of an Annals article, excluding editorials. Submitted new manuscripts will not enter the review process until the submission fee has been paid. . There will be no processing fee associated with resubmitted manuscripts.
HIGHLIGHTED VIDEO OF THE MONTH
Lymphatic Mapping and Sentinel Node Biopsy in the Colonic Mesentery by Natural Orifice Transluminal Endoscopic Surgery (NOTES) by R. A. Cahill MD, FRCS, S. Perretta MD, J. Leroy MD, B. Dallemagne MD, and J. Marescaux MD, FRCS, FACS. Annals of Surgical Oncology. Volume 15, Number 10, DOI: 10.1245/s10434-008-9952-8
Annals of Surgical Oncology is copyrighted by the Society of Surgical Oncology
© Springer Healthcare Ltd. A part of Springer Science+Business Media